Blocking PD-1/PD-L1 in Genitourinary Malignancies: To Immunity and Beyond

Area of Science:

• Oncology
• Immunology
• Urology

Background:

• Genitourinary (GU) malignancies exhibit diverse biological and immunological characteristics.
• Immune checkpoint blockade has revolutionized treatment for bladder and kidney cancers.
• Response to PD-1/PD-L1 axis inhibition is variable in bladder and kidney cancers, necessitating further advancements.

Purpose of the Study:

• To review the immune tumor microenvironment in bladder, kidney, and prostate cancers.
• To summarize key completed and ongoing clinical trials of anti-PD-1/PD-L1 therapy in these GU malignancies.
• To translate insights from tumor biology into improved clinical trial strategies.

Main Methods:

• Review of current literature on genitourinary cancer immunology.
• Analysis of clinical trial data for anti-PD-1/PD-L1 therapies.
• Exploration of tumor microenvironment features in bladder, kidney, and prostate cancers.

Main Results:

• Checkpoint blockade has transformed treatment for bladder and kidney cancers.
• Response to PD-1/PD-L1 inhibition is inconsistent, with only a minority of patients benefiting.
• Anti-PD-1/PD-L1 therapy studies in prostate cancer have yielded generally disappointing results to date.

Conclusions:

• Continued progress in bladder and kidney cancer treatment is essential.
• Understanding the immune tumor microenvironment is crucial for developing effective therapies.
• Ongoing studies aim to leverage tumor biology insights for promising clinical trials in GU cancers.